Integrated BioPharma (INBP) 10-K 20 Sep 24 2024 FY Annual report Financial data

Document And Entity Information

Document And Entity Information - USD ($)	12 Months Ended
	Jun. 30, 2024	Sep. 20, 2024	Dec. 31, 2023
Document Information [Line Items]
Entity Central Index Key	0001016504
Entity Registrant Name	INTEGRATED BIOPHARMA INC
Amendment Flag	false
Current Fiscal Year End Date	--06-30
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Document Type	10-K
Document Annual Report	true
Document Period End Date	Jun. 30, 2024
Document Transition Report	false
Entity File Number	001-31668
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	22-2407475
Entity Address, Address Line One	225 Long Ave.
Entity Address, City or Town	Hillside
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	07205
City Area Code	888
Local Phone Number	319-6962
Title of 12(g) Security	Common Stock, $.002 par value per share
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 3,367,657
Entity Common Stock, Shares Outstanding		30,099,610
Auditor Firm ID	688
Auditor Name	Marcum LLP
Auditor Location	East Hanover, New Jersey

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ / shares in Thousands, $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Sales, net	$ 50,317	$ 50,672
Cost of sales	46,433	46,611
Gross profit	3,884	4,061
Selling and administrative expenses	3,633	3,941
Operating income	251	120
Other income (expense), net:
Interest income (expense), net	18	(14)
Other income	(1)	(6)
Total other income (expense), net	17	(20)
Income before income taxes	268	100
Income tax expense, net	156	134
Net income (loss)	$ 112	$ (34)
Basic net income (loss) per common share (in dollars per share)	$ 0	$ 0
Diluted net income (loss) per common share (in dollars per share)	$ 0	$ 0
Weighted average common shares outstanding - basic (in shares)	30,066,003	29,949,610
Add: Equivalent shares outstanding - stock options (in shares)	807,678	0
Weighted average common shares outstanding - diluted (in shares)	30,873,681	29,949,610

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Current Assets:
Cash	$ 1,677	$ 1,316
Accounts receivable, net	4,668	4,511
Inventories	11,244	10,261
Other current assets	286	284
Total current assets	17,875	16,372
Property and equipment, net	1,885	1,653
Operating lease right-of-use assets	1,790	2,623
Deferred tax assets, net	4,601	4,726
Security deposits and other assets	56	57
Total Assets	26,207	25,431
Current Liabilities:
Accounts payable	2,510	2,266
Accrued expenses and other current liabilities	2,661	1,632
Current portion of finance lease obligation	7	42
Operating Lease, Liability, Current	945	888
Total current liabilities	6,123	4,828
Finance lease obligation	0	7
Operating lease obligations	846	1,735
Total Liabilities	6,969	6,570
Commitments and Contingencies (Note 10)
Stockholders' Equity
Common Stock, $0.002 par value; 50,000,000 shares authorized; 30,134,510 and 29,984,510 shares issued, respectively and 30,099,610 and 29,949,610 shares outstanding, respectively	60	60
Additional paid-in-capital	51,504	51,239
Accumulated deficit	(32,227)	(32,339)
Less: Treasury stock, at cost, 34,900 shares	(99)	(99)
Total Stockholders' Equity	19,238	18,861
Total Liabilities and Stockholders' Equity	$ 26,207	$ 25,431

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Operating lease right-of-use assets	$ 1,790	$ 2,623
Current portion of operating lease liabilities	945	888
Operating lease liabilities	$ 846	$ 1,735
Common stock, par value (in dollars per share)	$ 0.002	$ 0.002
Common stock, authorized (in shares)	50,000,000	50,000,000
Common stock, issued (in shares)	30,134,510	29,984,510
Common stock, outstanding (in shares)	30,099,610	29,949,610
Treasury stock, shares (in shares)	34,900	34,900
Vitamin Realty LLC [Member]
Operating lease right-of-use assets	$ 1,289	$ 2,061
Current portion of operating lease liabilities	804	772
Operating lease liabilities	$ 485	$ 1,289

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	Treasury Stock, Common [Member]	Total
Balance (in shares) at Jun. 30, 2022	29,984,510			34,900
Balance at Jun. 30, 2022	$ 60	$ 50,919	$ (32,305)	$ (99)	$ 18,575
Compensation expense for employee stock options	0	320	0	0	320
Net income (loss)	$ 0	0	(34)	$ 0	$ (34)
Shares issued upon exercise of stock options (in shares)					0
Balance (in shares) at Jun. 30, 2023	29,984,510			34,900
Balance at Jun. 30, 2023	$ 60	51,239	(32,339)	$ (99)	$ 18,861
Compensation expense for employee stock options	0	252	0	0	252
Net income (loss)	$ 0	0	112	$ 0	$ 112
Shares issued upon exercise of stock options (in shares)	150,000			0	150,000
Shares issued upon exercise of stock options	$ 0	13	0	$ 0	$ 13
Balance (in shares) at Jun. 30, 2024	30,134,510			34,900
Balance at Jun. 30, 2024	$ 60	$ 51,504	$ (32,227)	$ (99)	$ 19,238

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Cash flows from operating activities:
Net income (loss)	$ 112	$ (34)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Amortization of operating lease right-of-use assets	902	803
Depreciation and amortization	319	351
Deferred income taxes (benefit)	125	72
Accretion of financing instruments, amortization of prepaid financing costs and other	12	12
Compensation expense on employee stock options	252	320
Unrealized (gain) loss on investment in iBio Stock	0	(27)
Realized loss on sale of iBio Stock	0	35
Bad debt (charge offs) expense, net	(36)	3
Gain on disposal of fixed assets	1	(1)
Changes in operating assets and liabilities:
Accounts receivable	(120)	374
Inventories	(983)	794
Prepaid expenses and other assets	(12)	34
Operating lease obligations	(902)	(804)
Accounts payable	244	(921)
Accrued expenses and other current liabilities	1,029	221
Net cash provided by operating activities	943	1,232
Cash flows from investing activities:
Purchase of property and equipment	(553)	(116)
Proceeds from sale of iBio Stock	0	4
Proceeds from sale of fixed assets	0	1
Net cash used in investing activities	(553)	(111)
Cash flows from financing activities:
Repayments of advances under revolving credit facility, net	0	(101)
Proceeds from exercises of stock options	13	0
Repayments under financed lease obligations	(42)	(35)
Net cash used in financing activities	(29)	(136)
Net increase in cash	361	985
Cash at beginning of fiscal year	1,316	331
Cash at end of fiscal year	1,677	1,316
Supplemental disclosures of cash flow information:
Interest	42	41
Income taxes	37	0
Supplemental disclosures of non-cash transactions:
Acquisition of right-of-use asset, net and operating lease obligations, net	60	1,560
Trade in value on like-kind exchanges	$ 1	$ 0

Insider Trading Arrangements

Insider Trading Arrangements	12 Months Ended
	Jun. 30, 2024
Insider Trading Arr Line Items
Material Terms of Trading Arrangement [Text Block]	Item 9B. None
Rule 10b5-1 Arrangement Adopted [Flag]	false
Non-Rule 10b5-1 Arrangement Adopted [Flag]	false
Rule 10b5-1 Arrangement Terminated [Flag]	false
Non-Rule 10b5-1 Arrangement Terminated [Flag]	false

Note 1 - Business

Note 1 - Business	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]	Note 1. Integrated BioPharma, Inc., a Delaware corporation (together with its subsidiaries, the “Company”), is engaged primarily in the business of manufacturing, distributing, marketing and sales of vitamins, nutritional supplements and herbal products. The Company’s customers are located primarily in the United States and Luxembourg. The Company was originally incorporated in the state of Delaware on August 31, 1995 December 5, 2000, January 29, 2003, June 2006. The Company’s business segments include: (a) Contract Manufacturing operated by Manhattan Drug Company, Inc. (“MDC”), which manufactures vitamins and nutritional supplements for sale to distributors, multilevel marketers and specialized health-care providers and (b) Other Nutraceutical Businesses which includes the operations of (i) AgroLabs, Inc. (“AgroLabs”), which distributed healthful nutritional products for sale through major mass market, grocery and drug and vitamin retailers, under the following brands: Peaceful Sleep, Wheatgrass and other products introduced into the market using the AgroLabs name (these are referred to as our branded products), (ii) The Vitamin Factory (the “Vitamin Factory”), which sold private label MDC products, as well as our AgroLabs products, through the Internet, (iii) IHT Health Products, Inc. (“IHT”) a distributor of fine natural botanicals, including multi minerals produced under a license agreement, (iv) MDC Warehousing and Distribution, Inc., a service provider for warehousing and fulfillment services and (v) Chem International, Inc. (“Chem”), a distributor of certain raw materials for DSM Nutritional Products LLC. The Vitamin Factory had no June 30, 2024 2023.

Note 2 - Summary of Significant

Note 2 - Summary of Significant Accounting Policies	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Significant Accounting Policies [Text Block]	Note 2. Principles of Consolidation. Reclassifications. Use of Estimates. not ● sales returns and allowances; ● allowance for credit losses; ● inventory valuation; ● valuation and recoverability of long-lived assets; ● income taxes and valuation allowance on deferred income taxes, and; ● accruals for, and the probability of, the outcome of current litigation, if any. On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates. Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606. Shipping and Handling Costs. June 30, 2024 2023, Stock-Based Compensation. two three Income Taxes not not The Company files a U.S. federal income tax return as well as returns for various states. The Company’s income taxes have not 2017 2019, June 30, 2024 2023. Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component. Earnings Per Share. Fair Value of Financial Instruments. not In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value. Accounts Receivable and Allowance for Credit Losses. no 9 June 30, 2024 2023 Inventories. first first Property and Equipment. Building 15 Years Leasehold Improvements Shorter of estimated useful life or term of lease Machinery and Equipment 7 Years Transportation Equipment 5 Years Impairment of Long-Lived Assets. may not No June 30, 2024 2023 Investment in iBio, Inc. 2016 01 July 1, 2018, August 2008. 2016 01, June 30, 2024 2023, June 30, 2024 2023, June 30, 2024 2023, not Accounting Pronouncements Adopted None Accounting Pronouncements Not In November 2023, 2023 07 280 280 July 1, 2024, In December 2023, 2023 09 740 July 1, 2025

Note 3 - Inventories

Note 3 - Inventories	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Inventory Disclosure [Text Block]	Note 3. Inventories are stated at the lower of cost or net realizable value using the first first June 30, 2024 2023 Raw materials $ 7,888 $ 6,859 Work-in-process 2,449 2,148 Finished goods 907 1,254 Total $ 11,244 $ 10,261

Note 4 - Property and Equipment

Note 4 - Property and Equipment, Net	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Property, Plant and Equipment Disclosure [Text Block]	Note 4. Property and equipment consists of the following: June 30, 2024 2023 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,341 1,371 Machinery and equipment 7,224 6,801 9,815 9,422 Less: Accumulated depreciation and amortization (7,930 ) (7,769 ) Total $ 1,885 $ 1,653 Depreciation and amortization expense was $319 and $351 for the fiscal years ended June 30, 2024 2023, June 30, 2024 2023, not June 30, 2024 2023.

Note 5 - Senior Credit Facility

Note 5 - Senior Credit Facility	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Debt Disclosure [Text Block]	Note 5. As of June 30, 2024 2023, On May 9, 2024, June 27, 2012, February 19, 2016, May 15, 2019, June 28, 2019 March 16, 2023. The Amended Loan Agreement provides for a total of $5,000 ($8,000 as of June 30, 2023) June 30, 2023) ( June 30, 2024 2023, 0.10% Upon and after the occurrence of any event of default under the Amended Loan Agreement, and during the continuation thereof, interest shall be payable at the interest rate then applicable plus 2%. The Senior Credit Facility matures on May 9, 2026 ( The principal balance of the Revolving Advances is payable on the Senior Maturity Date, subject to acceleration, based upon a material adverse event clause, as defined, subjective accelerations for borrowing base reserves, as defined or upon the occurrence of any event of default under the Amended Loan Agreement or earlier termination of the Amended Loan Agreement pursuant to the terms thereof. The Revolving Advances are subject to the terms and conditions set forth in the Amended Loan Agreement and are made in aggregate amounts at any time equal to the lesser of ( x June 30, 2023) one may In connection with the Senior Credit Facility, the following loan documents were executed: (i) a Stock Pledge Agreement with PNC, pursuant to which the Company pledged to PNC the iBio Stock; (ii) a Mortgage and Security Agreement with PNC with IHT Properties; and (iii) an Environmental Indemnity Agreement with PNC.

Note 6 - Interest Expense

Note 6 - Interest Expense	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Interest Expense [Text Block]	Note 6. The components of interest expense for the fiscal years ended June 30, 2024 2023 For the Fiscal Year Ended June 30, 2024 2023 Interest on Senior Debt $ 40 $ 40 Amortization of prepaid financing costs 12 12 Interest Expense $ 52 $ 52 The weighted average interest rate paid was 5.97% and 5.67% in the fiscal years ended June 30, 2024 2023, June 30, 2024 2023, no

Note 7 - Income Taxes

Note 7 - Income Taxes	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Income Tax Disclosure [Text Block]	Note 7. The components of the provision for income taxes consists of the following: For the fiscal year ended June 30, 2024 2023 Current - Federal tax expense $ - $ - Current - State tax expense 31 61 Deferred - Federal tax expense 124 55 Deferred - State tax expense 1 18 Income tax expense, net $ 156 $ 134 A reconciliation of the statutory tax rate to the effective tax rate is as follows: For the fiscal year ended June 30, 2024 2023 Statutory federal income tax rate 21.0 % 21.0 % State income tax rate 25.6 % 74.6 % Stock compensation 21.1 % 166.0 % Change in valuation allowance (61.6 )% (188.0 )% Write-off of valuation allowance 62.1 % 18.0 % Federal and state true-up (10.4 )% 11.4 % Loss on sale of iBio Stock - 18.4 % Non-deductible expenses 0.6 % 12.6 % Effective income tax rate 58.4 % 134.0 % Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial accounting purposes and the amounts used for income tax reporting. Significant components of the Company’s net deferred tax assets are as follows: June 30, 2024 2023 Deferred Tax Assets Net operating loss $ 5,032 $ 5,105 Capital loss carryover 678 678 Depreciation (149 ) (139 ) Inventory 161 180 Other 150 337 Valuation allowance (1,271 ) (1,435 ) Total deferred tax asset, net $ 4,601 $ 4,726 The Company has net operating losses (“NOL”) of approximately $21,345 for federal purposes which expire beginning in 2028, 2018. 2018 80% no 2018. 2031 2039. 2025, 2026 2028, June 30, 2021, Realization of the NOL carryforwards and other deferred tax temporary differences is contingent on future taxable earnings. The Company’s deferred tax asset was reviewed for expected utilization using a “more likely than not” not” not The Company will continue to assess and evaluate strategies that will enable the deferred tax asset, or portion thereof, to be utilized, and will reduce the valuation allowance appropriately at such time when it is determined that the “more likely than not” There were no significant uncertain tax positions taken, or expected to be taken, in a tax return that would be determined to be an unrecognized tax benefit taken or expected to be taken in a tax return that should have been recorded on the Company’s consolidated financial statements for the year ended June 30, 2024. June 30, 2024 2023. The latest three four June 30, 2024 June 30, 2024 March 15, 2025.

Note 8 - Profit-sharing Plan

Note 8 - Profit-sharing Plan	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Retirement Benefits [Text Block]	Note 8. The Company maintains a profit-sharing plan, which qualifies under Section 401 June 30, 2024 2023,

Note 9 - Significant Risks and

Note 9 - Significant Risks and Uncertainties	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Concentration Risk Disclosure [Text Block]	Note 9. (a) Concentrations of Credit Risk-Cash. June 30, 2024, (b) Concentrations of Credit Risk-Receivables. not (c) Major Customers. June 30, 2024 2023, two two June 30, 2024 2023, two June 30, 2024 2023. not June 30, 2024 2023, (d) Business Risks. not The raw materials used by the Company are primarily commodities and agricultural-based products. Raw materials used by the Company in the manufacture of its nutraceutical products are purchased from independent suppliers. Raw materials are available from numerous sources and the Company believes that it will continue to obtain adequate supplies. As of June 30, 2024, September 1, 2022 August 31, 2026. The Company has seen a negative impact in its margins due to inflation, shipping delays and tightened labor markets. The Company may not may may The Company continues to experience minimal supply chain disruptions relating to transportation issues as it pertains to international shipping of certain raw materials used in the Company’s manufacturing process. These issues first 19 During the first 2022, Additionally, the current Israel-Hamas war in the Middle East could negatively impact the sales and margins of the Company. Certain customers sell into Israel and the Company sources certain raw materials from Israel. If the Israel-Hamas war carries on for a significant time frame, it could have a negative impact on the sales and margins of the Company if the Company is unable to replace these sales with other sales and/or obtain the same raw materials at substantially the same price as currently paid.

Note 10 - Lease Commitments and

Note 10 - Lease Commitments and Contingencies	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Commitments and Contingencies Disclosure [Text Block]	Note 10. (a) Leases. The components of lease expense for the fiscal year ended June 30, 2024 2023 2024 2023 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 842 $ 163 $ 1,005 $ 842 $ 88 $ 930 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 12 $ 12 $ - $ 12 $ 12 Total Finance Lease Costs $ - $ 12 $ 12 $ - $ 12 $ 12 Rent and lease amortization costs are included in cost of sales and selling and administrative expenses in the accompanying Condensed Consolidated Statements of Operations. Operating Lease Liabilities Related Party Operating Lease Liabilities. January 5, 2012, second January 31, 2026. July 15, 2022, third July 1, 2022. On May 19, 2014, January 5, 2012, January 31, 2020 June 1, 2024. July 15, 2022 July 1, 2022. Rent expense, lease amortization costs and imputed interest costs on these related party leases were $1,292 and $1,269 for the fiscal years ended June 30, 2024 2023, June 30, 2024 2023, June 30, 2024 2023, Other Operating Lease Liabilities. May 2027, As of June 30, 2024, Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 1,289 $ 804 $ 485 $ 1,334 Warehouse Lease 433 116 317 494 Transportation Lease 55 17 39 63 Office equipment leases 13 8 5 14 $ 1,790 $ 945 $ 846 $ 1,905 As of June 30, 2023, Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 2,061 $ 772 $ 1,289 $ 2,176 Warehouse Lease 541 108 433 631 Office equipment leases 21 8 13 23 $ 2,623 $ 888 $ 1,735 $ 2,830 As of June 30, 2024 2023, Financed Lease Obligation. On June 15, 2022, August 15, 2024. September 15, 2022 As of each June, 2024 2023, Supplemental cash flows information related to leases for the fiscal year ended June 30, 2024 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 842 $ 219 $ 1,061 Operating cash flows from finance lease obligations - - - Financing cash flows from finance lease obligations - 42 42 Supplemental cash flows information related to leases for the fiscal year ended June 30, 2023 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 842 $ 147 $ 989 Operating cash flows from finance lease obligations - - - Financing cash flows from finance lease obligations - 35 35 In the fiscal year ended June 30, 2024, four Maturities of operating lease liabilities as of June 30, 2024 Year ending June 30, Operating Lease Commitment Related Party Operating Lease Commitment Finance Lease Obligation Total 2025 $ 169 $ 842 $ 7 $ 1,018 2026 169 492 - 661 2027 169 - - 169 2028 64 - - 64 Total minimum lease payments 571 1,334 7 1,912 Imputed interest (70 ) (45 ) - (115 ) Total $ 501 $ 1,289 $ 7 $ 1,797 (b) Legal Proceedings. The Company is subject, from time to time, to claims by third

Note 11 - Related Party Transac

Note 11 - Related Party Transactions	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Related Party Transactions Disclosure [Text Block]	Note 11. Information related to related party transactions are disclosed in Note 10

Note 12 - Equity Transactions a

Note 12 - Equity Transactions and Stock-based Compensation	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Equity [Text Block]	Note 12. Stock Option Plans. 2001 1997 may not ten 10% five June 30, 2024, In the fiscal year ended June 30, 2024, three one ten June 30, 2024 2023, two In August 2024, one September 30, 2024, December 21, 2024, March 31, 2025 June 30, 2025. The Company used the following assumptions to calculate the fair value of the stock option grants using the Black-Scholes option pricing model on the measurement date during the year ended June 30, 2024: Risk Free Interest Rate 3.90% to 4.36 % Volatility 116.5% to 131.7 % Term 7.5 10.0 Dividend Rate 0.00 % Closing Price of Common Stock $ 0.24 to 0.33 The Company calculates expected volatility for a stock-based grant based on historic daily stock price observations of its common stock during the period immediately preceding the grant that is equal in length to the expected term of the grant. The expected term of the options is estimated based on the Company’s historical exercise rate and forfeiture rates are estimated based on employment termination experience. The risk free interest rate is based on U.S. Treasury yields for securities in effect at the time of grants with terms approximating the term of the grants. The assumptions used in the Black-Scholes option valuation model are highly subjective, and can materially affect the resulting valuations. In the fiscal year ended June 30, 2023, one three five ten In the fiscal years ended June 30, 2024 2023, not The intrinsic value of options outstanding and exercisable at June 30, 2024 2023 A summary of the Company’s stock option activity, and related information for the years ended June 30, Weighted Average Exercise Options Price Outstanding as of July 1, 2022 4,443,933 $ 0.36 Granted 527,000 0.42 Exercised - - Terminated - - Expired (594,649 ) 0.46 Outstanding as of June 30, 2023 4,376,284 0.35 Granted 782,500 0.27 Exercised (150,000 ) 0.09 Terminated (18,000 ) 0.53 Expired (241,601 ) 0.44 Outstanding as of June 30, 2024 4,749,183 $ 0.34 Exercisable at June 30, 2023 3,626,551 $ 0.30 Exercisable at June 30, 2024 3,804,150 $ 0.34 The following table summarizes the range of exercise prices and weighted-average exercise prices for stock options outstanding and exercisable as of June 30, 2024 Weighted Weighted Weighted Average Average Average Remaining Exercise Range of Exercise Price Outstanding Exercise Price Contractual Life (years) Exercisable Price $ 0.09 - $ 0.09 1,071,000 $ 0.09 0.9 1,071,000 $ 0.09 $ 0.21 - $ 0.21 1,194,000 0.21 4.9 1,194,000 0.21 $ 0.23 - $ 0.23 100,000 0.23 2.4 100,000 0.23 $ 0.24 - $ 0.26 582,500 0.25 9.4 - - # 0.33 - $ 0.33 200,000 0.33 9.1 200,000 0.33 $ 0.41 - $ 0.41 414,334 0.41 8.1 140,334 0.41 $ 0.51 - $ 0.51 200,000 0.51 8.0 200,000 0.51 $ 0.65 - $ 0.65 566,333 0.65 6.4 566,333 0.65 $ 0.95 - $ 0.95 421,016 0.95 7.1 332,483 0.95 $ 0.09 - $ 0.95 4,749,183 $ 0.34 8.1 3,804,150 $ 0.34

Note 13 - Segment Information

Note 13 - Segment Information	12 Months Ended
	Jun. 30, 2024
Notes to Financial Statements
Segment Reporting Disclosure [Text Block]	Note 13. The basis for presenting segment results generally is consistent with overall Company reporting. The Company reports information about its operating segments in accordance with GAAP which establishes standards for reporting information about a company’s operating segments. The Company has divided its operations into two June 30, 2024 2023 Financial information relating to the fiscal years ended June 30, 2024 2023 Sales, Net Segment U.S. International Gross Capital Total Customers Customers Total Profit Depreciation Expenditures Assets Contract Manufacturing 2024 $ 40,622 $ 7,946 $ 48,568 $ 3,702 $ 317 $ 550 $ 20,830 2023 40,230 8,047 48,277 3,630 348 109 19,507 Other Nutraceutical Businesses 2024 1,722 27 1,749 182 2 3 5,377 2023 2,387 8 2,395 431 3 7 5,924 Total Company 2024 42,344 7,973 50,317 3,884 319 553 26,207 2023 42,617 8,055 50,672 4,061 351 116 25,431

Significant Accounting Policies

Significant Accounting Policies (Policies)	12 Months Ended
	Jun. 30, 2024
Accounting Policies [Abstract]
Consolidation, Policy [Policy Text Block]	Principles of Consolidation.
Reclassification, Comparability Adjustment [Policy Text Block]	Reclassifications.
Use of Estimates, Policy [Policy Text Block]	Use of Estimates. not ● sales returns and allowances; ● allowance for credit losses; ● inventory valuation; ● valuation and recoverability of long-lived assets; ● income taxes and valuation allowance on deferred income taxes, and; ● accruals for, and the probability of, the outcome of current litigation, if any. On a continual basis, management reviews its estimates utilizing currently available information, changes in facts and circumstances, historical experience and reasonable assumptions. After such reviews, and if deemed appropriate, those estimates are adjusted accordingly. Actual results could differ from those estimates.
Revenue from Contract with Customer [Policy Text Block]	Revenue Recognition. 606, five ● identification of the promised goods or services in the contract; ● determination of whether the promised goods or serves are performance obligations including whether they are distinct in the context of the contract; ● measurement of the transaction price, including the constraint on variable consideration; ● allocation of the transaction price to the performance obligations based on estimated selling prices; and ● recognition of revenue when (or as) the Company satisfies each performance obligation. A performance obligation is a promise to transfer a distinct good or service to the customer and is the unit of account in ASC 606.
Cost of Goods, Shipping and Handling Costs [Policy Text Block]	Shipping and Handling Costs. June 30, 2024 2023,
Share-Based Payment Arrangement [Policy Text Block]	Stock-Based Compensation. two three
Income Tax, Policy [Policy Text Block]	Income Taxes not not The Company files a U.S. federal income tax return as well as returns for various states. The Company’s income taxes have not 2017 2019, June 30, 2024 2023.
Lessee, Leases [Policy Text Block]	Leases. Operating lease ROU assets and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most of our leases do not may We have lease agreements with lease and non-lease components, which are generally accounted for separately. For certain equipment leases, such as vehicles, we account for the lease and non-lease components as a single lease component.
Earnings Per Share, Policy [Policy Text Block]	Earnings Per Share.
Fair Value of Financial Instruments, Policy [Policy Text Block]	Fair Value of Financial Instruments. not In assessing the fair value of financial instruments, the Company uses a variety of methods and assumptions, which are based on estimates of market conditions and risks existing at the time. For certain instruments, including cash and cash equivalents, accounts receivable, accounts payable, and accrued expenses, it was estimated that the carrying amount approximated fair value because of the short maturities of these instruments. All debt is based on current rates at which the Company could borrow funds with similar remaining maturities and approximates fair value.
Loans and Leases Receivable, Allowance for Loan Losses Policy [Policy Text Block]	Accounts Receivable and Allowance for Credit Losses. no 9 June 30, 2024 2023
Inventory, Policy [Policy Text Block]	Inventories. first first
Property, Plant and Equipment, Policy [Policy Text Block]	Property and Equipment. Building 15 Years Leasehold Improvements Shorter of estimated useful life or term of lease Machinery and Equipment 7 Years Transportation Equipment 5 Years
Goodwill and Intangible Assets, Policy [Policy Text Block]	Impairment of Long-Lived Assets. may not No June 30, 2024 2023
Investment, Policy [Policy Text Block]	Investment in iBio, Inc. 2016 01 July 1, 2018, August 2008. 2016 01, June 30, 2024 2023, June 30, 2024 2023, June 30, 2024 2023, not
New Accounting Pronouncements, Policy [Policy Text Block]	Accounting Pronouncements Adopted None Accounting Pronouncements Not In November 2023, 2023 07 280 280 July 1, 2024, In December 2023, 2023 09 740 July 1, 2025

Note 3 - Inventories (Tables)

Note 3 - Inventories (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Inventory, Current [Table Text Block]	June 30, 2024 2023 Raw materials $ 7,888 $ 6,859 Work-in-process 2,449 2,148 Finished goods 907 1,254 Total $ 11,244 $ 10,261

Note 4 - Property and Equipme_2

Note 4 - Property and Equipment, Net (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Property, Plant and Equipment [Table Text Block]	June 30, 2024 2023 Land and building $ 1,250 $ 1,250 Leasehold improvements 1,341 1,371 Machinery and equipment 7,224 6,801 9,815 9,422 Less: Accumulated depreciation and amortization (7,930 ) (7,769 ) Total $ 1,885 $ 1,653

Note 6 - Interest Expense (Tabl

Note 6 - Interest Expense (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Interest Expense Disclosure Table [Table Text Block]	For the Fiscal Year Ended June 30, 2024 2023 Interest on Senior Debt $ 40 $ 40 Amortization of prepaid financing costs 12 12 Interest Expense $ 52 $ 52

Note 7 - Income Taxes (Tables)

Note 7 - Income Taxes (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]	For the fiscal year ended June 30, 2024 2023 Current - Federal tax expense $ - $ - Current - State tax expense 31 61 Deferred - Federal tax expense 124 55 Deferred - State tax expense 1 18 Income tax expense, net $ 156 $ 134
Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]	For the fiscal year ended June 30, 2024 2023 Statutory federal income tax rate 21.0 % 21.0 % State income tax rate 25.6 % 74.6 % Stock compensation 21.1 % 166.0 % Change in valuation allowance (61.6 )% (188.0 )% Write-off of valuation allowance 62.1 % 18.0 % Federal and state true-up (10.4 )% 11.4 % Loss on sale of iBio Stock - 18.4 % Non-deductible expenses 0.6 % 12.6 % Effective income tax rate 58.4 % 134.0 %
Schedule of Deferred Tax Assets and Liabilities [Table Text Block]	June 30, 2024 2023 Deferred Tax Assets Net operating loss $ 5,032 $ 5,105 Capital loss carryover 678 678 Depreciation (149 ) (139 ) Inventory 161 180 Other 150 337 Valuation allowance (1,271 ) (1,435 ) Total deferred tax asset, net $ 4,601 $ 4,726

Note 10 - Lease Commitments a_2

Note 10 - Lease Commitments and Contingencies (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Lease, Cost [Table Text Block]	2024 2023 Related Party - Vitamin Realty Other Leases Totals Related Party - Vitamin Realty Other Leases Totals Operating Lease Costs $ 842 $ 163 $ 1,005 $ 842 $ 88 $ 930 Finance Operating Lease Costs: Amortization of right-of use assets $ - $ 12 $ 12 $ - $ 12 $ 12 Total Finance Lease Costs $ - $ 12 $ 12 $ - $ 12 $ 12
Leases and Remaining Commitments [Table Text Block]	Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 1,289 $ 804 $ 485 $ 1,334 Warehouse Lease 433 116 317 494 Transportation Lease 55 17 39 63 Office equipment leases 13 8 5 14 $ 1,790 $ 945 $ 846 $ 1,905 Right-of-use Assets Current Portion Operating Lease Obligations Operating Lease Obligations Remaining Cash Commitment Vitamin Realty Leases $ 2,061 $ 772 $ 1,289 $ 2,176 Warehouse Lease 541 108 433 631 Office equipment leases 21 8 13 23 $ 2,623 $ 888 $ 1,735 $ 2,830
Supplemental Cash Flow Information, Leases [Table Text Block]	Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 842 $ 219 $ 1,061 Operating cash flows from finance lease obligations - - - Financing cash flows from finance lease obligations - 42 42 Related Party - Vitamin Realty Other Leases Totals Cash paid for amounts included in the measurement of lease liabilities: Operating cash flows from operating leases $ 842 $ 147 $ 989 Operating cash flows from finance lease obligations - - - Financing cash flows from finance lease obligations - 35 35
Lessee, Operating Lease and Finance Lease, Liability, Maturity [Table Text Block]	Year ending June 30, Operating Lease Commitment Related Party Operating Lease Commitment Finance Lease Obligation Total 2025 $ 169 $ 842 $ 7 $ 1,018 2026 169 492 - 661 2027 169 - - 169 2028 64 - - 64 Total minimum lease payments 571 1,334 7 1,912 Imputed interest (70 ) (45 ) - (115 ) Total $ 501 $ 1,289 $ 7 $ 1,797

Note 12 - Equity Transactions_2

Note 12 - Equity Transactions and Stock-based Compensation (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	Risk Free Interest Rate 3.90% to 4.36 % Volatility 116.5% to 131.7 % Term 7.5 10.0 Dividend Rate 0.00 % Closing Price of Common Stock $ 0.24 to 0.33
Share-Based Payment Arrangement, Option, Activity [Table Text Block]	Weighted Average Exercise Options Price Outstanding as of July 1, 2022 4,443,933 $ 0.36 Granted 527,000 0.42 Exercised - - Terminated - - Expired (594,649 ) 0.46 Outstanding as of June 30, 2023 4,376,284 0.35 Granted 782,500 0.27 Exercised (150,000 ) 0.09 Terminated (18,000 ) 0.53 Expired (241,601 ) 0.44 Outstanding as of June 30, 2024 4,749,183 $ 0.34 Exercisable at June 30, 2023 3,626,551 $ 0.30 Exercisable at June 30, 2024 3,804,150 $ 0.34
Share-Based Payment Arrangement, Option, Exercise Price Range [Table Text Block]	Weighted Weighted Weighted Average Average Average Remaining Exercise Range of Exercise Price Outstanding Exercise Price Contractual Life (years) Exercisable Price $ 0.09 - $ 0.09 1,071,000 $ 0.09 0.9 1,071,000 $ 0.09 $ 0.21 - $ 0.21 1,194,000 0.21 4.9 1,194,000 0.21 $ 0.23 - $ 0.23 100,000 0.23 2.4 100,000 0.23 $ 0.24 - $ 0.26 582,500 0.25 9.4 - - # 0.33 - $ 0.33 200,000 0.33 9.1 200,000 0.33 $ 0.41 - $ 0.41 414,334 0.41 8.1 140,334 0.41 $ 0.51 - $ 0.51 200,000 0.51 8.0 200,000 0.51 $ 0.65 - $ 0.65 566,333 0.65 6.4 566,333 0.65 $ 0.95 - $ 0.95 421,016 0.95 7.1 332,483 0.95 $ 0.09 - $ 0.95 4,749,183 $ 0.34 8.1 3,804,150 $ 0.34

Note 13 - Segment Information (

Note 13 - Segment Information (Tables)	12 Months Ended
	Jun. 30, 2024
Notes Tables
Schedule of Segment Reporting Information, by Segment [Table Text Block]	Sales, Net Segment U.S. International Gross Capital Total Customers Customers Total Profit Depreciation Expenditures Assets Contract Manufacturing 2024 $ 40,622 $ 7,946 $ 48,568 $ 3,702 $ 317 $ 550 $ 20,830 2023 40,230 8,047 48,277 3,630 348 109 19,507 Other Nutraceutical Businesses 2024 1,722 27 1,749 182 2 3 5,377 2023 2,387 8 2,395 431 3 7 5,924 Total Company 2024 42,344 7,973 50,317 3,884 319 553 26,207 2023 42,617 8,055 50,672 4,061 351 116 25,431

Note 1 - Business (Details Text

Note 1 - Business (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Revenue from Contract with Customer, Including Assessed Tax	$ 50,317	$ 50,672
Revenue from Contract with Customer, Including Assessed Tax	50,317	50,672
Branded Products [Member]
Revenue from Contract with Customer, Including Assessed Tax	0	0
Revenue from Contract with Customer, Including Assessed Tax	$ 0	$ 0

Note 2 - Summary of Significa_2

Note 2 - Summary of Significant Accounting Policies (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Aug. 31, 2008
Cost of Goods and Services Sold	$ 46,433	$ 46,611
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	3 years
Liability for Uncertainty in Income Taxes, Current	$ 0	0
Accounts Receivable, Allowance for Credit Loss	1	37
Impairment of Intangible Assets, Finite-Lived	0	0
Cost Method Investment, Ownership Percentage			6%
Realized Investment Gains (Losses)	0	(35)
Unrealized Gain (Loss) on Investments	$ 0	27
Building and Building Improvements [Member]
Property, Plant and Equipment, Useful Life (Year)	15 years
Machinery and Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	7 years
Air Transportation Equipment [Member]
Property, Plant and Equipment, Useful Life (Year)	5 years
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | MDC [Member]
Income Tax Examination, Year under Examination	2014
State and Local Jurisdiction [Member] | New Jersey Division of Taxation [Member] | CII [Member]
Income Tax Examination, Year under Examination	2016
Shipping and Handling [Member]
Cost of Goods and Services Sold	$ 821	$ 1,006

Note 3 - Inventories - Inventor

Note 3 - Inventories - Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Raw materials	$ 7,888	$ 6,859
Work-in-process	2,449	2,148
Finished goods	907	1,254
Total	$ 11,244	$ 10,261

Note 4 - Property and Equipme_3

Note 4 - Property and Equipment, Net (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Depreciation	$ 319	$ 351
Gain (Loss) on Disposition of Property Plant Equipment	(1)	1
Fully Depreciated Property [Member]
Property, Plant and Equipment, Disposals	134	26
Gain (Loss) on Disposition of Property Plant Equipment	(1)	0
Property Not Fully Depreciated [Member]
Property, Plant and Equipment, Disposals	27	0
Equipment [Member]
Gain (Loss) on Disposition of Property Plant Equipment	$ (1)	$ (1)

Note 4 - Property and Equipme_4

Note 4 - Property and Equipment, Net - Property and Equipment, Net (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Property and equipment, gross	$ 9,815	$ 9,422
Less: Accumulated depreciation and amortization	(7,930)	(7,769)
Total	1,885	1,653
Land and Building [Member]
Property and equipment, gross	1,250	1,250
Leasehold Improvements [Member]
Property and equipment, gross	1,341	1,371
Machinery and Equipment [Member]
Property and equipment, gross	$ 7,224	$ 6,801

Note 5 - Senior Credit Facili_2

Note 5 - Senior Credit Facility (Details Textual) - Amended Loan Agreement [Member] - USD ($) $ in Thousands			12 Months Ended
	May 09, 2024	May 15, 2019	Jun. 30, 2024	Jun. 30, 2023
Senior Notes			$ 0	$ 0
Debt Instrument, Face Amount	$ 5,000			8,000
Debt Instrument, Basis Spread on Variable Rate			0.10%
Debt Instrument, Debt Default, Interest Rate Basic Spread		2%
Revolving Credit Facility [Member]
Line of Credit Facility, Maximum Borrowing Capacity	5,000			$ 8,000
Line of Credit Facility, Interest Rate at Period End			8.50%	8.25%
Line of Credit Facility Covenant Maximum Aggregate Revolving Advance	$ 5,000		$ 8,000
Line of Credit Facility Covenant Aggregate Revolving Advance Receivables Advance Rate	85%
Line of Credit Facility Covenant Aggregate Revolving Advance Inventory Advance Rate	75%
Line of Credit Facility, Covenan,t Aggregate Revolving Advance, Appraised Liquidation Value, Inventory Advance Rate	85%

Note 6 - Interest Expense (Deta

Note 6 - Interest Expense (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Interest Payable	$ 0	$ 0
Debt Related to Interest Expense [Member]
Debt, Weighted Average Interest Rate	5.97%	5.67%

Note 6 - Interest Expense - Int

Note 6 - Interest Expense - Interest Expense Components (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Amortization of prepaid financing costs	$ 12	$ 12
Interest Expense	52	52
Senior Notes [Member]
Interest Expense, Long-Term Debt	$ 40	$ 40

Note 7 - Income Taxes (Details

Note 7 - Income Taxes (Details Textual) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Liability for Uncertainty in Income Taxes, Current	$ 0	$ 0
Income Tax Examination, Penalties and Interest Accrued	0	$ 0
Capital Loss Carryforward [Member]
Tax Credit Carryforward, Amount	2,343
Capital Loss Carryforward [Member] | Tax Year 2025 [Member]
Tax Credit Carryforward, Amount	271
Capital Loss Carryforward [Member] | Tax Year 2026 [Member]
Tax Credit Carryforward, Amount	1,152
Capital Loss Carryforward [Member] | Tax Year 2028 [Member]
Tax Credit Carryforward, Amount	920
Domestic Tax Jurisdiction [Member]
Operating Loss Carryforwards	21,345
State and Local Jurisdiction [Member]
Operating Loss Carryforwards	$ 4,005

Note 7 - Income Taxes - Compone

Note 7 - Income Taxes - Components of the Provision for Income Taxes (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Current - Federal tax expense	$ 0	$ 0
Current - State tax expense	31	61
Deferred - Federal tax expense	124	55
Deferred - State tax expense	1	18
Income tax expense, net	$ 156	$ 134

Note 7 - Income Taxes - Reconci

Note 7 - Income Taxes - Reconciliation of the Statutory Tax Rate to the Effective Tax Rate (Details)	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Statutory federal income tax rate	21%	21%
State income tax rate	25.60%	74.60%
Stock compensation	21.10%	166%
Change in valuation allowance	(61.60%)	(188.00%)
Write-off of valuation allowance	62.10%	18%
Federal and state true-up	(10.40%)	11.40%
Loss on sale of iBio Stock	0%	18.40%
Non-deductible expenses	0.60%	12.60%
Effective income tax rate	58.40%	134%

Note 7 - Income Taxes - Signifi

Note 7 - Income Taxes - Significant Components of Deferred Tax Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Net operating loss	$ 5,032	$ 5,105
Capital loss carryover	678	678
Depreciation	(149)	(139)
Inventory	161	180
Other	150	337
Valuation allowance	(1,271)	(1,435)
Total deferred tax asset, net	$ 4,601	$ 4,726

Note 8 - Profit-sharing Plan (D

Note 8 - Profit-sharing Plan (Details Textual) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Defined Contribution Plan, Employer Discretionary Contribution Amount	$ 80	$ 81

Note 9 - Significant Risks an_2

Note 9 - Significant Risks and Uncertainties (Details Textual) $ in Thousands	12 Months Ended
	Jun. 30, 2024 USD ($)	Jun. 30, 2023
Cash, FDIC Insured Amount	$ 250
Cash, Uninsured Amount	$ 2,137
Revenue Benchmark [Member] | Customer Concentration Risk [Member]
Number of Major Customers	2
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage	90%	89%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	71%	70%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Other Nutraceutical Business [Member]
Concentration Risk, Percentage	43%	56%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Contract Manufacturing [Member]
Concentration Risk, Percentage	23%	24%
Revenue Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 2 [Member] | Other Nutraceutical Business [Member]
Concentration Risk, Percentage	14%	16%
Accounts Receivable [Member] | Customer Concentration Risk [Member] | Two Customers [Member]
Concentration Risk, Percentage	84%	84%
Revenue, Segment Benchmark [Member] | Customer Concentration Risk [Member] | Major Customer 1 [Member] | Branded Nutraceutical [Member]
Concentration Risk, Percentage	10%
Number of Employees, Geographic Area [Member] | Unionized Employees Concentration Risk [Member]
Concentration Risk, Percentage	76%

Note 10 - Lease Commitments a_3

Note 10 - Lease Commitments and Contingencies (Details Textual) $ in Thousands					12 Months Ended
	May 19, 2024 USD ($) a	Jul. 01, 2022 USD ($)	Jun. 15, 2022 USD ($)	Jan. 05, 2012 USD ($) ft²	Jun. 30, 2024 USD ($)	Jun. 30, 2023 USD ($)	Jul. 15, 2023 ft²	Jan. 04, 2012 ft²
Operating Lease, Liability, Current					$ 945	$ 888
Finance Lease, Liability					$ 7
Transportation Equipment [Member]
Lessee, Operating Lease, Term of Contract (Year)					4 years
Lessee, Operating Lease, Liability, Annual Commitment					$ 21
Unrelated Party [Member]
Operating Lease, Liability					$ 501
Lessee, Operating Lease, Discount Rate					5%	4.41%
Operating Lease, Weighted Average Remaining Lease Term (Year)					2 years	2 years 10 months 24 days
Finance Lease, Liability			$ 85
Debt Instrument, Periodic Payment			$ 4
Debt Instrument, Interest Rate, Stated Percentage			0%
Lessee, Finance Lease, Discount Rate					0%	0%
Finance Lease, Weighted Average Remaining Lease Term (Year)					2 months 12 days	1 year 2 months 12 days
Vitamin Realty LLC [Member]
Operating Lease, Expense					$ 1,292	$ 1,269
Operating Lease, Liability, Current					0	0
Operating Lease, Liability					$ 1,289	$ 2,061
Manhattan Drug Company [Member]
Area of Real Estate Property (Square Foot) | ft²				76,161			116,175	74,898
Payments for Rent		$ 842		$ 533
AgroLabs [Member]
Area of Real Estate Property (Square Foot) | a	2,700
Payments for Rent	$ 27
Chairman, Chief Executive Office and Major Stockholder [Member]
Percent of Ownership for Warehouse and Office Facilities Leased					100%
Minimum [Member]
Lessee, Lease, Term of Contract (Year)					1 year
Maximum [Member]
Lessee, Lease, Term of Contract (Year)					7 years

Note 10 - Commitments and Conti

Note 10 - Commitments and Contingencies - Lease Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating Lease Costs	$ 1,005	$ 930
Amortization of right-of use assets	12	12
Total Finance Lease Costs	12	12
Unrelated Party [Member]
Operating Lease Costs	163	88
Amortization of right-of use assets	12	12
Total Finance Lease Costs	12	12
Vitamin Realty LLC [Member]
Operating Lease Costs	842	842
Amortization of right-of use assets	0	0
Total Finance Lease Costs	$ 0	$ 0

Note 10 - Commitments and Con_2

Note 10 - Commitments and Contingencies - Leases and Commitments (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 30, 2023
Right-of-use assets	$ 1,790	$ 2,623
Operating Lease, Liability, Current	945	888
Operating lease obligations	846	1,735
Remaining cash commitment	1,905	2,830
Warehouse Lease [Member]
Right-of-use assets		541
Operating Lease, Liability, Current		108
Operating lease obligations		433
Remaining cash commitment		631
Transportation Equipment Lease [Member]
Right-of-use assets	55
Operating Lease, Liability, Current	17
Operating lease obligations	39
Remaining cash commitment	63
Office Equipment Leases [Member]
Right-of-use assets	13	21
Operating Lease, Liability, Current	8	8
Operating lease obligations	5	13
Remaining cash commitment	14	23
Vitamin Realty LLC [Member]
Right-of-use assets	1,289	2,061
Operating Lease, Liability, Current	804	772
Operating lease obligations	485	1,289
Remaining cash commitment	1,334	$ 2,176
Warehouse Lease [Member]
Right-of-use assets	433
Operating Lease, Liability, Current	116
Operating lease obligations	317
Remaining cash commitment	$ 494

Note 10 - Commitments and Con_3

Note 10 - Commitments and Contingencies - Supplemental Cash Flow Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Operating cash flows from operating leases	$ 1,061	$ 989
Operating cash flows from finance lease obligations	0	0
Financing cash flows from finance lease obligations	42	35
Unrelated Party [Member]
Operating cash flows from operating leases	219	147
Operating cash flows from finance lease obligations	0	0
Financing cash flows from finance lease obligations	42	35
Vitamin Realty LLC [Member]
Operating cash flows from operating leases	842	842
Operating cash flows from finance lease obligations	0	0
Financing cash flows from finance lease obligations	$ 0	$ 0

Note 10 - Commitments and Con_4

Note 10 - Commitments and Contingencies - Minimum Rental Commitment for Long-term Non-cancelable Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2024	Jun. 15, 2022
2025, Finance Lease Obligation	$ 7
2025	1,018
2026, Finance Lease Obligation	0
2026	661
2027, Finance Lease Obligation	0
2027	169
2028, Finance Lease Obligation	0
2028	64
Total minimum lease payments, Finance Lease Obligation	7
Total minimum lease payments	1,912
Imputed interest, Finance Lease Obligation	0
Imputed interest	(115)
Total, Finance Lease Obligation	7
Total	1,797
Vitamin Realty LLC [Member]
2025, Operating Lease	842
2026, Operating Lease	492
2027, Operating Lease	0
2028, Operating Lease	0
Total minimum lease payments, Operating Lease	1,334
Imputed interest, Operating Lease	(45)
Total, Operating Lease	1,289
Unrelated Party [Member]
2025, Operating Lease	169
2026, Operating Lease	169
2027, Operating Lease	169
2028, Operating Lease	64
Total minimum lease payments, Operating Lease	571
Imputed interest, Operating Lease	(70)
Total, Operating Lease	$ 501
Total, Finance Lease Obligation		$ 85

Note 12 - Equity Transactions_3

Note 12 - Equity Transactions and Stock-based Compensation (Details Textual) - USD ($)	1 Months Ended	12 Months Ended
	Aug. 31, 2024	Jun. 30, 2024	Jun. 30, 2023
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		6,351,818
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		782,500	527,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.27	$ 0.42
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		3 years
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value		$ 129,000	$ 461,000
Director [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	200,000
Each Director [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)	50,000
Maximum [Member] | Director [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 0.2
Minimum [Member] | Director [Member] | Subsequent Event [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)	$ 0.18
Share-Based Payment Arrangement, Option [Member]
Share-Based Payment Arrangement, Expense		252,000	$ 320,000
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount		$ 205
Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)		2 years 6 months
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)		2,101,683	4,376,284
Share-Based Payment Arrangement, Option [Member] | Director [Member] | Subsequent Event [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)	1 year
Share-Based Payment Arrangement, Option [Member] | Director [Member] | Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche One [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	25%
Share-Based Payment Arrangement, Option [Member] | Director [Member] | Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche Four [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	25%
Share-Based Payment Arrangement, Option [Member] | Director [Member] | Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche Three [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	25%
Share-Based Payment Arrangement, Option [Member] | Director [Member] | Subsequent Event [Member] | Share-Based Payment Arrangement, Tranche Two [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Award Vesting Rights, Percentage	25%
Share-Based Payment Arrangement, Option [Member] | Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
Share-Based Payment Arrangement, Option [Member] | Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years
Stock Option 2001 Plan [Member]
Share Based Compensation Arrangement by Share Based Payment Award Number of Shares Originally Authorized (in shares)		7,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)		6,000,000
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		13,000,000
Stock Option 1997 Plan [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		5,000,000
Stock Option 2024 Plan [Member] | Officers and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		592,500
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		582,500
Stock Option 2024 Plan [Member] | Non-executive Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Authorized (in shares)		200,000
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)		200,000
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.33
Stock Option 2024 Plan [Member] | Maximum [Member] | Officers and Employees [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		0.26
Stock Option 2024 Plan [Member] | Minimum [Member] | Officers and Employees [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)		$ 0.24
Stock Option 2024 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Officers and Employees [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		3 years
Stock Option 2024 Plan [Member] | Share-Based Payment Arrangement, Option [Member] | Non-executive Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)		1 year
Stock Option Plan 2023 [Member] | Director [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.33
Stock Option Plan 2023 [Member] | Officers, Employees, and Directors [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross (in shares)			738,500
Stock Option Plan 2023 [Member] | Officer [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.41
Stock Option Plan 2023 [Member] | Employees [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)			$ 0.45
Stock Option Plan 2023 [Member] | Share-Based Payment Arrangement, Option [Member] | Maximum [Member] | Officers, Employees, and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		10 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			3 years
Stock Option Plan 2023 [Member] | Share-Based Payment Arrangement, Option [Member] | Minimum [Member] | Officers, Employees, and Directors [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)		5 years
Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)			1 year

Note 12 - Equity Transactions_4

Note 12 - Equity Transactions and Stock-based Compensation - Fair Value of Stock Option Using Black-Scholes Option Pricing Model (Details)	12 Months Ended
	Jun. 30, 2024 $ / shares
Dividend Rate	0%
Minimum [Member]
Risk Free Interest Rate	3.90%
Volatility	116.50%
Term (Year)	7 years 6 months
Closing Price of Common Stock (in dollars per share)	$ 0.24
Maximum [Member]
Risk Free Interest Rate	4.36%
Volatility	131.70%
Term (Year)	10 years
Closing Price of Common Stock (in dollars per share)	$ 0.33

Note 12 - Equity Transactions_5

Note 12 - Equity Transactions and Stock-based Compensation - Summary of the Company's Stock Option Activity, and Related Information (Details) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Balance (in shares)	4,376,284	4,443,933
Balance, weighted average exercise price (in dollars per share)	$ 0.35	$ 0.36
Granted (in shares)	782,500	527,000
Granted, weighted average exercise price (in dollars per share)	$ 0.27	$ 0.42
Exercised (in shares)	(150,000)	0
Exercised, weighted average exercise price (in dollars per share)	$ 0.09	$ 0
Terminated (in shares)	(18,000)	0
Terminated, weighted average exercise price (in dollars per share)	$ 0.53	$ 0
Expired (in shares)	(241,601)	(594,649)
Expired, weighted average exercise price (in dollars per share)	$ 0.44	$ 0.46
Balance (in shares)	4,749,183	4,376,284
Balance, weighted average exercise price (in dollars per share)	$ 0.34	$ 0.35
Exercisable (in shares)	3,804,150	3,626,551
Exercisable, weighted average exercise price (in dollars per share)	$ 0.34	$ 0.3

Note 12 - Equity Transactions_6

Note 12 - Equity Transactions and Stock-based Compensation - Share-based Compensation, Shares Authorized under Stock Option Plans, by Exercise Price Range (Details) - $ / shares	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2022
Range of Exercise Price, Lower Limit (in dollars per share)	$ 0.09
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.95
Outstanding (in shares)	4,749,183	4,376,284	4,443,933
Weighted average exercise price (in dollars per share)	$ 0.34	$ 0.35	$ 0.36
Weighted Average Remaining Contractual Life (Year)	8 years 1 month 6 days
Exercisable (in shares)	3,804,150	3,626,551
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.34	$ 0.3
Range One [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.09
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.09
Outstanding (in shares)	1,071,000
Weighted average exercise price (in dollars per share)	$ 0.09
Weighted Average Remaining Contractual Life (Year)	10 months 24 days
Exercisable (in shares)	1,071,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.09
Range Two [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.21
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.21
Outstanding (in shares)	1,194,000
Weighted average exercise price (in dollars per share)	$ 0.21
Weighted Average Remaining Contractual Life (Year)	4 years 10 months 24 days
Exercisable (in shares)	1,194,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.21
Range Three [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.23
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.23
Outstanding (in shares)	100,000
Weighted average exercise price (in dollars per share)	$ 0.23
Weighted Average Remaining Contractual Life (Year)	2 years 4 months 24 days
Exercisable (in shares)	100,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.23
Range Four [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.24
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.26
Outstanding (in shares)	582,500
Weighted average exercise price (in dollars per share)	$ 0.25
Weighted Average Remaining Contractual Life (Year)	9 years 4 months 24 days
Exercisable (in shares)	0
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0
Range Five [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.33
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.33
Outstanding (in shares)	200,000
Weighted average exercise price (in dollars per share)	$ 0.33
Weighted Average Remaining Contractual Life (Year)	9 years 1 month 6 days
Exercisable (in shares)	200,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.33
Range Six [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.41
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.41
Outstanding (in shares)	414,334
Weighted average exercise price (in dollars per share)	$ 0.41
Weighted Average Remaining Contractual Life (Year)	8 years 1 month 6 days
Exercisable (in shares)	140,334
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.41
Range Seven [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.51
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.51
Outstanding (in shares)	200,000
Weighted average exercise price (in dollars per share)	$ 0.51
Weighted Average Remaining Contractual Life (Year)	8 years
Exercisable (in shares)	200,000
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.51
Range Eight [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.65
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.65
Outstanding (in shares)	566,333
Weighted average exercise price (in dollars per share)	$ 0.65
Weighted Average Remaining Contractual Life (Year)	6 years 4 months 24 days
Exercisable (in shares)	566,333
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.65
Range Nine [Member]
Range of Exercise Price, Lower Limit (in dollars per share)	0.95
Range of Exercise Price, Upper Limit (in dollars per share)	$ 0.95
Outstanding (in shares)	421,016
Weighted average exercise price (in dollars per share)	$ 0.95
Weighted Average Remaining Contractual Life (Year)	7 years 1 month 6 days
Exercisable (in shares)	332,483
Weighted Average Exercise Price, Exercisable (in dollars per share)	$ 0.95

Note 13 - Segment Information_2

Note 13 - Segment Information (Details Textual)	12 Months Ended
	Jun. 30, 2024 $ / shares	Jun. 30, 2023 $ / shares
Number of Reportable Segments	2
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)	$ 0.44	$ 0.46
Europe and Canada [Member]
Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Expirations in Period, Weighted Average Exercise Price (in dollars per share)	$ 7,973	$ 8,055

Note 13 - Segment Information -

Note 13 - Segment Information - Operations by Business Segment (Details) - USD ($) $ in Thousands	12 Months Ended
	Jun. 30, 2024	Jun. 30, 2023
Sales, net	$ 50,317	$ 50,672
Gross Profit	3,884	4,061
Depreciation	319	351
Capital Expenditures	553	116
Assets	26,207	25,431
Contract Manufacturing [Member]
Sales, net	48,568	48,277
Gross Profit	3,702	3,630
Depreciation	317	348
Capital Expenditures	550	109
Assets	20,830	19,507
Other Nutraceutical Business [Member]
Sales, net	1,749	2,395
Gross Profit	182	431
Depreciation	2	3
Capital Expenditures	3	7
Assets	5,377	5,924
UNITED STATES
Sales, net	42,344	42,617
UNITED STATES | Contract Manufacturing [Member]
Sales, net	40,622	40,230
UNITED STATES | Other Nutraceutical Business [Member]
Sales, net	1,722	2,387
Non-US [Member]
Sales, net	7,973	8,055
Non-US [Member] | Contract Manufacturing [Member]
Sales, net	7,946	8,047
Non-US [Member] | Other Nutraceutical Business [Member]
Sales, net	$ 27	$ 8